<DOC>
	<DOCNO>NCT01260298</DOCNO>
	<brief_summary>The objective study observe body contour change follow treatment use MC1 device .</brief_summary>
	<brief_title>Protocol To Evaluate Patient Measurements After Ultrasonic Treatment</brief_title>
	<detailed_description>The purpose research study observe body contour change follow treatment use MC1 device . The MC1 System FDA clear relief minor muscle ache , pain muscle spasm , temporary improvement local blood circulation , temporary reduction appearance cellulite .</detailed_description>
	<criteria>1 . Is female . 2 . Is 20 50 year age , inclusive , day enrolment . 3 . Has BMI 20 30 kg/m2 . 4 . Is treated infrascapular area use MC1 . 5 . Has never treat MC1 . 1 . Patient lactating , positive pregnancy test within 7 day plan study procedure ( female patient childbearing potential ) , intend become pregnant study use effective method prevent pregnancy . 2 . Currently enrol another device drug study complete required followup period , complete studyrequired followup less 30 day enrolment study . 3 . Keloid scar , hypertrophic scar history abnormal healing . 4 . Thrombophlebitis . 5 . Bleeding bruise disorder ( e.g . idiopathic thrombocytopenic purpura , anticoagulated patient ) . 6 . Tissue ischemia area treat . 7 . Hypertension abnormally high blood pressure . 8 . High cholesterol . 9 . Active collagen vascular disease ( e.g . fibromyalgia , panniculitis , lupus etc. ) . 10 . Diabetes . 11 . Epilepsy . 12 . Tuberculosis . 13 . Auxiliary electric organ ( pacemaker ) , metal myoelectric prosthesis . 14 . Endocrine syndromes thyroid hyperfunction . 15 . Any type hemorrhagic ( bleed ) status . 16 . Active skin infection , infection treat area within last 30 day skin disease area treat ( e.g . eczema , psoriasis , urticaria , dermographism ) . 17 . Hepatic renal insufficiency . 18 . Bone , muscle joint disease , dysfunction heal area treat . 19 . Malignancy area treat . 20 . Laminectomy area treat . 5.2 . Withdrawal Replacement Subjects</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>MC1 VASER VASERShape</keyword>
</DOC>